GlassScriptPhysician profile
Michael Giblin
NPI 1366817611
$6,904.55
in general payments reported to CMS, 2019-2025
46 companies · $1,235 in 2025
The $1,235 reported for 2025 was more than what 86% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,142 · 2022: $1,579 · 2023: $511 · 2024: $1,438 · 2025: $1,235.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,184.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,184.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,165.61 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $811.03 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Astrazeneca Pharmaceuticals LP | $598.87 | 2021-2025 | Airsupra, Farxiga, Breztri |
| Abbvie INC. | $579.44 | 2021-2025 | |
| Amgen INC. | $339.55 | 2021-2025 | Evenity, Prolia, Krystexxa |
| Pfizer INC. | $241.56 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $203.89 | 2021-2022 | |
| Xeris Pharmaceuticals, INC. | $201.53 | 2021-2022 | |
| Amarin Pharma, INC. | $198.12 | 2021-2022 | |
| Mannkind Corporation | $186.82 | 2021-2022 | |
| Astellas Pharma US INC | $182.02 | 2024-2025 | Veozah |
| Sanofi-Aventis U.S. LLC | $150.33 | 2021-2022 | |
| Medtronic, INC. | $148.84 | 2025 | Minimed 780g |
| Beta Bionics, INC. | $145.99 | 2024 | Ilet Bionic Pancreas |
| Otsuka America Pharmaceutical, INC. | $129.32 | 2023-2025 | Rexulti |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Giblin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.